Treatment of insulin resistance with peroxisome proliferator-activated receptor γ agonists

Journal of Clinical Investigation

Volumn 106, Issue 4, 2000, Pages 467-472

  Olefsky, Jerrold M ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; HISTONE; PARTIAL AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PIOGLITAZONE; RECEPTOR BLOCKING AGENT; ROSIGLITAZONE; TROGLITAZONE;

ACETYLATION; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; GENE MUTATION; HORMONE ACTION; HUMAN; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SYNDROME X;

EID: 0033857387     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI10843     Document Type: Review

References (49)

1. Olefsky, J.M. 1997. Insulin resistance. In Ellenberg and Rifkin's Diabetes Mellitus; theory and practice. 5th edition. D. Porte and R.S. Sherwin, editors. Medical Examination Publishing Co., New Hyde Park, New York, USA. 151-178.
2. Reaven, G.M. 1988. Role of insulin resistance in human disease. Diabetes. 37:1595-1607.
3. Taylor, S.I. 1999. Deconstructing type 2 diabetes. Cell. 97:9-12.
4. Warram, J.H., Martin, B.C., Krolewski, A.S., Soeldner, J.S., and Kahn, C.R. 1990. Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents. Ann. Intern. Med. 13:909-915.
5. Kruszynska, Y., Yu, J.G., Olefsky, J.M., and Sobel, B.E. 2000. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects. Diabetes. 49:633-639.
6. Saltiel, A.R., and Olefsky, J.M. 1996. Thiazolidinediones in the treatment of insulin resistance and Type II diabetes. Diabetes. 45:1661-1669.
7. Spiegelman, B.M. 1998. PPAR-γ: adipogenic regulator and thiazolidinedione receptor. Diabetes. 47:507-514.
8. Lowell, B.B. 1999. PPARγ: an essential regulator of adipogenesis and modulator of fat cell function. Cell. 99:230-253.
9. Fujiwara, T., et al. 1991. Characterization of CS-045, a new oral antidiabetic agent. II. Effects on glycemic control and pancreatic islet structure at a late stage of the diabetic syndrome in C57BL/KsJ-db/db mice. Metabolism. 40:1213-1218.
10. Fujiwara, T., Yoshioka, S., Yoshioka, T., Ushiyama, I., and Horikoshi, H. 1988. Characterization of new oral antidiabetic agent CS-045: studies in KK and ob/ob mice and Zucker fatty rats. Diabetes. 37:1549-1558.
11. Lee, M.-K., et al. 1994. Metabolic effects of troglitazone on fructose-induced insulin resistance in the rat. Diabetes. 43:1435-1439.
12. Miles, P.D.G., et al. 1997. TNF-α-induced insulin resistance in vivo and its prevention by troglitazone. Diabetes. 44:1678-1683.
13. Miles, P.G., et al. 1998. Troglitazone prevents hyperglycemia-induced but not glucosamin-induced insulin resistance. Diabetes. 47:395-400.
14. Kraegen, E.W., James, D.E., Jenkins, A.B., Chisholm, D.J., and Storlien, L.H. 1989. A potent in vivo effect of ciglitazone on muscle insulin resistance induced by high at feeding of rats. Metabolism. 38:1089-1093.
15. Suter, S., Nolan, J., Wallace, P., Gumbiner, B., and Olefsky, J.M. 1992. Metabolic effects of a new oral hypoglycemic agent, CS-045, in non-insulin dependent diabetic subjects. Diabetes Care. 15:193-203.
16. Iwamoto, Y., et al. 1991. Effects of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM. Diabetes Care. 14:1083-1086.
17. Sironi, A.M., et al. 1997. Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes. Clin. Pharmacol. Ther. 62:194-202.
18. Maggs, D.G., et al. 1998. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus: a randomized, double-blind placebo-controlled trial. Ann. Intern. Med. 128:176-185.
19. Nolan, J.J., Ludvik, B., Beerdsen, P., Joyce, M., and Olefsky, J.M. 1994. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N. Engl. J. Med. 333:1188-1193.
20. Ehrmann, D.A., et al. 1997. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 82:2108-2116.
21. Berkowitz, K., et al. 1996. Effect of troglitazone on insulin sensitivity and pancreatic beta cell function in women at high risk for NIDDM. Diabetes. 45:1572-1579.
22. Ginsberg, H.N. 2000. Insulin resistance and cardiovascular disease. J. Clin. Invest. 106:453-458.
23. Kumar, S., et al. 1996. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Troglitazone Study Group. Diabetologia. 39:701-709.
24. Ibrahimi, A., et al. 1994. Evidence for a common mechanism of action for fatty acids and thiazolidinedione antidiabetic agents on gene expression in preadipose cells. Mol. Pharmacol. 46:1070-1076.
25. Braissant, O., Foufelle, F., Scott, C., Dauce, M., and Wahili, W. 1996. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-α β and γ in the adult rat. Endocrinology. 137:354-566.
26. Zhu, Y., et al. 1995. Structural organization of mouse peroxisome proliferator-artivated receptor gamma gene: alternative promoter use and different splicing yield two PPAR gamma isoforms. Proc. Natl. Acad. Sci. USA. 92:7921-7925.
27. Kliewer, S.A., et al. 1997. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ. Proc. Natl. Acad. Sci. USA. 94:4318-4325.
28. 12.14-prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ. Cell. 83:803-812.
29. Glass, C.K., and Rosenfeld, M.G. 2000. The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev. 14:121-141.
30. Kliewer, S.A., et al. 1994. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc. Natl. Acad. Sci. USA. 91:7355-7359.
31. Tontonoz, P., et al. 1994. Adipocyte-specific transcription factor ARF6 is a heterodimeric complex of two nuclear hormone receptors, PPARγ and RXRα. Nucleic Acids Res. 22:5628-5634.
32. Kruszynska, Y.T., et al. 1998. Skeletal muscle peroxisome proliferator-activated recepror-γ expression in obesity and non-insulin dependent diabetes mellitus. J. Clin. Invest. 101:543-548.
33. Vidal-Puig, A.J., et al. 1997. Peroxisome proliterator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J. Clin. Invest. 99:2416-2422.
34. Ciaraldi, T.P., Gilmore, A., Olefsky, J.M., Goldberg, M., and Heidenreich, K.A. 1990. In vitro studies on the action of CS-045. A new anti-diabetic agent. Metabolism. 39:1056-1062.
35. Burant, C.F., et al. 1997. Troglitazone action is independent of adipose tissue. J. Clin. Invest. 100:2900-2908.
36. Lee, M.-K., and Olefsky, J.M. 1995. Acute effects of troglitazone on in vivo insulin action in normal rats. Metabolism. 44:1166-1169.
37. Preininger, K., et al. 1999. Acute troglitazone action in isolated perfused rat liver. Br. J. Pharmacol. 126:372-378.
38. Kadowaki, T. 2000. Insights into insulin resistance and type 2 diabetes from knockout mouse models. J. Clin. Invest. 106:459-465.
39. Barak, Y., et al. 1999. PPARγ is required for placental, cardiac, and adipose tissue development. Mol. Cell. 4:585-595.
40. Miles, P.D.G., Barak, Y., Evans, R.M., and Olefsky, J.M. 2000. Improved insulin-sensitivity in mice heterozygous for PPARγ deficiency. J. Clin. Invest. 105:287-292.
41. Deeb, S.S., et al. 1998. A Pro 12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat. Genet. 20:284-287.
42. Ringel, J., Engeli, S., Distler, A., and Sharma, A.M. 1999. Pro12Ala missense mutation of the peroxisome proliterator activated receptor γ and diabetes mellitus. Biochem. Biophys. Res. Commun. 254:450-453.
43. Mori, Y., et al. 1998. Effect of the Pro 12Ala variant of the human peroxisome proliferator-activated receptor gamma 2 gene on adiposity, fat distribution, and insulin sensitivity in Japanese men. Biochem. Biophys. Res. Commun. 251:195-198.
44. Barroso, I., et al. 1999. Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes and hypertension. Nature. 402:880-883.
45. Nagy, L., et al. 1997. Nuclear receptor repression mediated by a complex containing SMRT, mSIN3AZ, and histone deacetylase. Cell. 89:373-380.
46. Camp, H.S., et al. 2000. Differential activation of peroxisome proliferator-activated receptor-γ by troglitazone and rosiglitazone. Diabetes. 49:539-547.
47. Strahl, B.D., and Allis, C.D. 2000. The language of covalent histone modifications. Nature. 403:41-45.
48. McDonnell, D.P. 1999. The molecular pharmacology of SERMs. Trends Endocrinol. Metab. 10:301-311.
49. Burant, C.F. 1999. Regulation of gene expression in vivo by PPAR gamma. Diabetes. 48(Suppl. 1):44.